Company intelligence / Profile preview

Tetraphase Pharmaceuticals, Inc.

Waltham, Massachusetts, United Statesxerava.com ↗

Ownership: Private
Employees: ~33
Development stage: Commercial

Overview

Tetraphase's lead product eravacycline (XERAVA) was approved for the treatment of complicated intra-abdominal infections by the FDA and European Commission. The drug failed to show non-inferiority in complicated urinary tract infection trials.

Therapeutic areas: HematologyInfectious Diseases
Modalities: Small molecules
Industry: Biotech

Drug pipeline

4 assets

eravacycline

Commercial

Indications: Complicated intra-abdominal infections

3 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Tetraphase Pharmaceuticals, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tetraphase Pharmaceuticals, Inc..

Explore the full profile